

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

November 19, 2021

**Friday, November 19, 2021**

|              |  |  |
|--------------|--|--|
| <b>12:00</b> | <b>Welcome &amp; Introductions</b>   | Dr. Grace Lee (ACIP Chair)<br>Dr. Melinda Wharton (ACIP Executive Secretary, CDC)                |
| <b>12:15</b> | <b>Coronavirus Disease 2019 (COVID-19) Vaccines</b><br>Introduction<br>Efficacy and safety of BNT 162b2 booster dose<br>Update from Moderna                    | Dr. Matthew Daley (ACIP, WG Chair)<br>Dr. John Perez (Pfizer)<br>Dr. Rituparna Das (Moderna)     |
| <b>12:50</b> | <b>Break</b>   |  |
| <b>1:00</b>  | <b>Public Comment</b>  |  |
| <b>1:20</b>  | <b>Break</b>   |  |
| <b>1:30</b>  | COVID-19 vaccine booster dose safety<br>VaST summary<br>Updates to the EtR Framework: Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses<br>Discussion | Dr. Tom Shimabukuro (CDC/NCEZID)<br>Dr. Keipp Talbot (VaST Chair)<br>Dr. Sara Oliver (CDC/NCIRD) |
| <b>2:45</b>  | <b><u>VOTE</u></b><br>COVID-19 vaccine booster doses   | Dr. Sara Oliver (CDC/NCIRD)  |
| <b>3:00</b>  | <b>Adjourn</b>   |  |

***Acronyms***

|            |  |
|------------|--|
| CDC        | Centers for Disease Control and Prevention                             |
| CMS        | Centers for Medicare and Medicaid Services                             |
| COVID-19   | Coronavirus disease 2019   |
| EtR        | Evidence to Recommendations Framework                                  |
| FDA        | Food and Drug Administration   |
| GRADE      | Grading of Recommendations Assessment, Development and Evaluation      |
| HRSA       | Health Resources and Services Administration                           |
| IHS        | Indian Health Service  |
| NCHHSTP    | National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] |
| NCIRD      | National Center for Immunization & Respiratory Diseases [of CDC/OID]   |
| NCEZID     | National Center for Emerging and Zoonotic Diseases [of CDC/OID]        |
| NIAID      | National Institute of Allergy and Infectious Diseases                  |
| OIDP       | Office of Infectious Disease and HIV/AIDS Policy                       |
| RZV        | Recombinant Zoster Vaccine   |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2                        |
| WG         | Work Group   |
| WHO        | World Health Organization  |
| VE         | Vaccine Effectiveness  |